Stocks and Investing Stocks and Investing
Tue, October 15, 2019
Mon, October 14, 2019
Fri, October 11, 2019

Andrew Berens Maintained (BPMC) at Buy with Decreased Target to $109 on, Oct 11th, 2019


Published on 2024-10-26 16:52:46 - WOPRAI, Andrew Berens
  Print publication without navigation


Andrew Berens of Morgan Stanley, Maintained "Blueprint Medicines Corporation" (BPMC) at Buy with Decreased Target from $110 to $109 on, Oct 11th, 2019.

Andrew has made no other calls on BPMC in the last 4 months.



There are 5 other peers that have a rating on BPMC. Out of the 5 peers that are also analyzing BPMC, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Christopher Raymond of "Piper Sandler" Initiated at Hold and Held Target at $85 on, Thursday, August 29th, 2019


These are the ratings of the 4 analyists that currently disagree with Andrew


  • Andrew Fein of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $100 on, Thursday, October 3rd, 2019
  • Dane Leone of "Raymond James" Upgraded from Hold to Buy on, Thursday, September 12th, 2019
  • Joel Beatty of "Baird" Initiated at Buy and Held Target at $120 on, Friday, July 19th, 2019
  • Konstantinos Aprilakis of "Deutsche Bank" Initiated at Strong Buy and Held Target at $110 on, Thursday, July 18th, 2019

Contributing Sources